In April 2022, Coala Life carried out a guaranteed rights issue of SEK 150 million. The net proceeds from the rights issue are mainly intended to be used to fund an accelerated market penetration in the US, research and development and general corporate purposes. The company’s goal is to have sales of SEK 250 million …
Coala Life announces today that the US Food & Drug Administration (FDA) has cleared additional indications and uses for the Coala Heart Monitor. The new FDA 510k clearance enables the system to be used for auscultation and monitoring of patients’ lungs remotely. The new functionality available is made immediately to existing and new users. Coala …
On March 16 at 1.50pm, Dan Pitulia, CEO of Coala Life will present the latest developments in the company at Redeye. The presentation is live broadcasted and can be followed at https://us02web.zoom.us/j/86991641341?pwd=WGx2V0c1aXkvbVhBQTdhdWhESGZiUT09 where the replay and the presentations will be available afterwards. For more info, please contact: Dan Pitulia, CEO Coala Life AB, +46 70 972 08 38, dan.pitulia@coalalife.com …
Coala-Life Group AB (publ), a leading company in cloud-based remote monitoring of heart and lung diseases, announces today that the TITAN-DM study – a clinical observational study aimed at increasing knowledge about the incidence of atrial fibrillation in people with diabetes – is now fully recruited with 600 participants. The study participants are followed with …
Trading started today following the reverse acquisition of Coala Life by RNB Retail and Brands AB (”RNB”). The listing followed the approval of Nasdaq and RNB is in process of changing name to Coala-Life Group AB (Nasdaq: COALA.ST).
Stockholm, October 7, 2021: Coala Life, a leading company in cloud-based remote monitoring of heart and lung diseases, is now conducting a clinical observational study in collaboration with researchers at the Gävleborg Region, Uppsala University and Karolinska Institute to increase knowledge about the incidence of atrial fibrillation in people with diabetes. The TITAN-DM study is …
Stockholm, September 27, 2021: Coala Life, a leader in the field of cloud-based remote patient monitoring of heart and lung diseases, is moving towards a future as a listed company, through a so-called reverse IPO process via an acquisition by RNB Retail and Brands AB (“RNB”) listed on Nasdaq in Sweden. The news, which was …
Coala Life today is pleased to announce the appointment of Jerome V. Dwyer, MD, MBA as Chief Medical Officer – Coala Life, Inc. Dr. Dwyer will oversee the continued development of Coala’s patient-centric solutions that use smart algorithms to digitally transform the field of cardiac diagnostics and help win the battle against the world’s leading …
Amy Davalle has been appointed the new President of Coala Life US. Amy joins the team to continue the scale-up of the US business. She brings very strong medical device expertise and leadership honed through her years at Guidant, Boston Scientific, Abbott, as well as, through senior positions within the start-up community. Philip Siberg, co-founder …
